iRhythm Holdings, Inc (IRTC) Stock AnalysisIRTCStock AnalysisiRhythm Holdings, Inc

iRhythm Holdings, Inc. is a digital healthcare company that creates trusted solutions that detect, predict, and prevent disease. The Company's principal business is the design, development, and commercialization of device-based technology to provide ambulatory cardiac monitoring services that allow clinicians to diagnose certain arrhythmias quicker and with greater efficiency than other services that rely on traditional technology. The Company provides Zio ambulatory cardiac monitoring services, including long-term continuous monitoring (LTCM), short-term continuous monitoring, and mobile cardiac telemetry (MCT) monitoring services, using a proprietary system that combines an FDA-cleared and CE-marked wire-free, patch-based, 14-day wearable biosensor that continuously records ECG data, with a proprietary FDA-cleared, CE-marked, Japan PDMA approved cloud-based data analytic software to help physicians monitor patients and diagnose arrhythmias. It operates in the Healthcare sector (SURGICAL & MEDICAL INSTRUMENTS & APPARATUS industry).

iRhythm Technologies Inc is a good buy right now due to its recent strong Q2 results, which showed sales of $224.17 million and a narrowed net loss of only $0.381 million. Additionally, the company raised its full-year revenue guidance to $880 million–$890 million, reflecting an expected growth of 18%-19% year-over-year. However, the stock has a high forward P/E ratio of 500, indicating that it may be overvalued if growth does not meet expectations.

4 analysts cover IRTC: 3 rate it Buy, 1 Hold and 0 Sell. The average price target is 222.00.